Tocagen Phase III study in brain cancer fails, sending shares plummeting
The company said Thursday morning that its study failed to meet its primary endpoint in high-grade gliomas. Shares of the company fell more than 80 percent on the Nasdaq.
What’s the fate of BeiGene’s PD-1 inhibitor after Bristol-Myers Squibb’s buyout of Celgene?
In an interview at the ASCO meeting, BeiGene chief adviser Eric Hedrick said the company is well-prepared for when it likely regains global rights to tislelizumab.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study
The drug was being tested in combination with radiation therapy among newly diagnosed patients with glioblastoma, a notoriously difficult-to-treat and invariably fatal disease.
BMS, Celgene tout synergies in $74B mega-deal, but Revlimid’s winter is coming
In a call to following news of the deal, executives pointed to near-term launch opportunities and pipelines, but some analysts expressed concern about the loss of patent protection for Revlimid and Opdivo.
Bristol-Myers Squibb to acquire Celgene in $74B deal
The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly oncology.
Vedanta Biosciences raises $27M in Series C round
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.